Molecule developed that helps target T-cells to fight brain cancer
T-Cell immunotherapy is a multi-billion dollar success. Companies are genetically engineering an individual’s own immune cells to attack cancer in the blood or lymph system. Chimeric antigen receptor T-cell therapy, or CAR-T therapy has seen huge acquisitions and investments. Gilead Sciences paid $11.9 billion for Kite Pharma, which received FDA approval for its own CAR-T …